14 Feb 2013, BioSpectrum Bureau , BioSpectrum
Mumbai: Glenmark Generics Europe (GGEL), launched its first generic drug, Atovaquone Proguanil, in the UK following the revocation of the Malarone patent in the High court in the UK.
The judgement has been handed down by the UK court in the case, that involved Glenmark Generics Europe, Glenmark Generics UK, and Mylan against the Wellcome Foundation and the Glaxo group.
The case involved the revocation of Glaxo's patent for its anti-malarial product Malarone. Following proceedings in the High Court, Mr. Justice Arnold revoked Glaxo's patent on the basis that it was obvious.
Atovaquone Proguanil is indicated for the prophylaxis and treatment of acute, uncomplicated P. falciparum malaria, particularly where there is likely to be resistance. IMS Health sales data for the 12 month period ending September 2012 estimates that Atovaquone Proguanil garnered sales of $27.89 million (Euro 20.69 million) in the UK.
Glenmark Generics Europe is part of Glenmark Generics. The European arm is headquartered in the UK and operates through its own entities and distribution partners in the UK, Germany, the Netherlands, Denmark, Sweden and Ireland. Glenmark Generics Europe has an exciting portfolio of more than 300 Marketing authorizations approved in Europe. In addition to these internal filings, GGEL continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.